Transepithelial photorefractive keratectomy for myopic retreatments after laser in situ keratomileusis
Session Details
Session Title: LASIK & PRK II
Session Date/Time: Monday 16/09/2019 | 14:00-16:00
Paper Time: 15:30
Venue: Free Paper Forum: Podium 3
First Author: : H.Kandil EGYPT
Co Author(s): :
Abstract Details
Purpose:
To evaluate the effectiveness, predictability and safety of Transepithelial Photorefractive Keratectomy (tPRK) for the myopic retreatment in eyes with previous myopic Laser in Situ Keratomileusis (LASIK).
Setting:
Department of Ophthalmology - Alexandria University
Alexandria ICare Hospital
Egypt
Methods:
This is a prospective non-comparative case series of 16 eyes of 9 patients who had tPRK retreatment for myopia or myopic astigmatism 2 to 10 years after primary myopic LASIK. Myopia ranged from -1.50 D to -3.50 D. Eyes with cylinder of >1.50 D were excluded. The procedure was performed using the Schwind Amaris 1050RS with a -0.5 D added to the spherical component of the refraction. All eyes had Mitomycin C (MMC) 0.02% application for 20 seconds. Postoperative uncorrected distance visual acuity (UDVA) and manifest refractions were measured. Corneal haze, contrast sensitivity and night vision problems were also recorded.
Results:
The mean preoperative sphere was -2.0±0.64 D (-1.50 to -3.50 D), the mean preoperative cylinder was 0.9±0.32 D (0.0 to 1.50 D) and the mean preoperative spherical equivalent (SE) was -2.4±0.7 D (-1.75 to -4.25 D). After tPRK, the sphere and cylinder were within ±0.50 D in 15 eyes and 10 eyes, respectively. The mean postoperative SE was -0.16±0.36 D (0 to -0.75D). At the final follow up visit, 10 eyes had an UDVA of 20/20 or better. None of the eyes lost any lines of vision. Corneal haze grade 1 was noticed in 7 eyes.
Conclusions:
Despite the uncertainty about epithelial thickening and irregularity in the previously treated corneas, Transepithelial PRK with MMC may be an effective and safe procedure in the myopic retreatments after LASIK. This is most beneficial in cases with insufficient stromal bed thickness and where flap relift is better avoided.
Financial Disclosure:
None